GPT and metabolic dysfunction-associated steatotic liver disease: In a recent meta-analysis of 12 randomized controlled trials estimating the efficacy of different SGLT2is on NAFLD and enrolling 850 overweight or obese individuals followed for 24 weeks, a decrease in ALT levels as well as fatty liver content was reported [28].